Claims

1. A medical product in the form of a sealed container containing an aqueous formulation of a peptide, or a pharmaceutically acceptable salt thereof, which:

a) consists of 9 amino acids in a linear arrangement;

b) of those 9 amino acids, 5 are cationic and 4 are lipophilic; and

c) of these 4 lipophilic amino acids, 3 are tryptophan and 1 is non-genetically coded.

2. The medical product of claim 1, wherein the cationic amino acids in the peptide are lysine or arginine and wherein the non-genetically coded amino acid in the peptide is diphenylalanine or biphenylalanine.

3. The medical product of any one of claims 1 to 2, wherein the peptide is selected from the group consisting of LTX-302, LTX-313, LTX-315, LTX-320 and LTX-329 and is preferably in the form of a pharmaceutically acceptable salt, preferably an acetate salt.

4. The medical product of any one of claims 1 to 3, wherein the peptide is LTX-315 having the amino acid sequence of SEQ ID NO: 23 and is in salt form, preferably an acetate salt.

5. The medical product of any one of claims 1 to 4, wherein the peptide is present in the aqueous formulation at a concentration of 1 to 30 mg/ml, preferably 4 to 20 mg/ml.

6. The medical product of any one of claims 1 to 5, wherein the aqueous formulation comprises water for injection or an aqueous buffer.

7. The medical product of any one of claims 1 to 6, wherein the aqueous formulation further comprises at least one excipient selected from the group consisting of: a salt, a preservative agent, a tonicity modifier, a stabilizer, an antioxidant, a viscosity enhancer and a chelating agent.

8. The medical product of any one of claims 1 to 7, wherein the aqueous formulation further comprises at least one viscosity enhancer, preferably wherein the viscosity enhancer is chitosan or a chitosan derivative.

9. The medical product of any one of claims 1 to 8, wherein the aqueous formulation has a viscosity of from 1 cP to 300 cP and/or wherein the pH of the aqueous formulation is from 5.0 to 7.4.

10. The medical product of any of claims 1 to 9, wherein the total amount of excipients present in the aqueous formulation is no more than 20% w/w, preferably no more than 5% w/w.

11. The medical product of any of claims 1 to 10, wherein the aqueous formulation comprises at least one organic excipient and the total amount of all such organic excipients is less than 10% w/w.

12. The medical product of any one of claims 1 to 11, wherein the aqueous formulation consists of the peptide and water, preferably water for injection, or consists of the peptide and an aqueous buffer.

13. The medical product of any one of claims 1 to 12, wherein the aqueous formulation is a sterile solution of the peptide, preferably a sterile, ready-to-inject solution of the peptide.

14. The medical product of any one of claims 1 to 13, wherein the container is sealed with a manufactured seal, preferably wherein the container is selected from the group consisting of pre-filled syringe, syringe cartridge, vial and ampoule.

15. The medical product of any one of claims 1 to 14, wherein the sealed container contains a volume of the aqueous formulation of 0.1 to 20 ml, preferably 0.2 to 10 ml or 0.2 to 5ml.

16. The medical product of any one of claims 1 to 15, wherein the sealed container contains a single dose.

17. The medical product of any one of claims 1 to 15, wherein the sealed container contains multiple doses.

18. A method of making the medical product according to any one of claims 1 to 17, wherein the aqueous formulation is introduced into the container and the filled container is mechanically sealed.

19. The use of a peptide, or a pharmaceutically acceptable salt thereof, which:

a) consists of 9 amino acids in a linear arrangement;

b) of those 9 amino acids, 5 are cationic and 4 are lipophilic; and

c) of these 4 lipophilic amino acids, 3 are tryptophan and 1 is non-genetically coded

for the manufacture of a medical product in the form of a sealed container containing a sterile, ready-to-inject aqueous formulation of said peptide or pharmaceutically acceptable salt thereof, for treating a tumour in a subject, wherein

the aqueous formulation contained in the sealed container is administered to the subject.

20. The use as claimed in claim 19, wherein the peptide is LTX-315 having the amino acid sequence of SEQ ID NO: 23 and is in salt form, preferably an acetate salt and the aqueous formulation is administered into the tumour of the subject.